Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration

Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim. Under the terms of the drug discovery contract, Evotec will receive a milestone payment from Boehringer Ingelheim which was granted for the selection of an advanced compound for profiling to enable the start of preclinical development.

Further projects within the multi-target collaboration are progressing and are on track to achieve additional project milestones for which Evotec is entitled to receive additional payments from Boehringer Ingelheim. Furthermore, the contract provides substantial long-term upside through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market. Further financial details of the payment were not disclosed.

Dr John Kemp, Chief Research and Development Officer at Evotec, commented: “We are proud to have achieved this important milestone in one of our projects with Boehringer Ingelheim. This further demonstrates our capabilities to discover novel drugs based on our drug discovery expertise. Our collaboration with Boehringer Ingelheim is progressing very well and we are looking forward to continued success.”

Evotec AG

Evotec AG
Neuroscience drug development

Website
www.evotec.com

Downloads

DownloadFull Press Release

Latest News

MVM Partners LLP Closes Fund V

MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.

Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test

Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.

Vertos MOTION study enrollment complete

Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis

HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO

HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.

Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15

Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.